2015
Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic‐induced weight gain in first‐episode psychosis patients: a meta‐analysis of differential effects of antipsychotic medications. Early Intervention In Psychiatry 2015, 10: 193-202. PMID: 25962699, PMCID: PMC5589463, DOI: 10.1111/eip.12251.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisAP medicationFEP patientsBody weight gainBMI increaseWeight gainAP useBody mass index (BMI) changeSignificant body weight gainWeight gain riskMore weight gainComprehensive literature searchMean weight gainMeta-regression analysisBaseline weightBMI changeModifiable factorsBMI differencesMedicationsBMI outcomesPlaceboHigher weight gainBMILiterature searchPatients
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss